We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Validation of RDQ Questionnaire

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00291746
Recruitment Status : Completed
First Posted : February 15, 2006
Last Update Posted : March 12, 2009
Information provided by:

February 14, 2006
February 15, 2006
March 12, 2009
September 2005
Not Provided
  • Selection of RDQ items (RDQ will be completed by subject at Screening and visit 4)
  • Presence/absence of GERD as assessed by endoscopic Los Angeles (LA) grade (gastroesophageal endoscopy will be performed at visit 2)
  • pH monitoring (% time with esophageal pH<4; Bravo pH-Monitoring will be performed from visit 2 to 3.1)
  • Symptom Associated Probability (outcome test for Bravo pH monitoring)
  • Outcome of PPI test (is assessed between visit 3.2 and 4.
Same as current
Complete list of historical versions of study NCT00291746 on ClinicalTrials.gov Archive Site
  • Mean item score for the GSRS dimensions at the initial and last visit (as assessed by answers of patient at visit 1 and visit 4)
  • RDQ item scores and RDQ mean item scores for RDQ dimensions at baseline and at the end of treatment (as assessed by answers of patient at Screening and visit 4)
  • Occurrence and severity of clinical symptoms at the initial and last visit (as reported by the subject)
Same as current
Not Provided
Not Provided
Validation of RDQ Questionnaire
A Single-Blind Single Arm Study to Validate the Reflux Disease Questionnaire (RDQ) for the Diagnosis of Reflux Disease in Primary Care in Patients Treated With Esomeprazole 40 mg o.d.
The primary objective of this study is to determine the accuracy of the Reflux Disease Questionnaire (RDQ) as a diagnostic test for gastroesophageal reflux disease. Symptom evaluation by the RDQ will be compared with other established approaches to the diagnosis of gastroesophageal reflux disease (GERD) in a primary care patient population with symptoms thought to be of upper gastrointestinal (GI) tract origin.
Not Provided
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Diagnostic
Gastroesophageal Reflux
  • Drug: Esomeprazole
  • Procedure: Bravo technique
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
November 2006
Not Provided

Inclusion Criteria:

  • Subjects who seek medical advice at their family doctor (primary care physician) for symptoms thought by the primary care physician to arise from the upper GI tract
  • The symptoms thought to pertain to the upper GI tract must have been present for at least 4 weeks prior to Visit 1 and to have occurred at least twice a week during that period
  • The symptoms thought to pertain to the upper GI tract must have been of at least mild severity for a minimum of 3 days during the week prior to Visit 1

Exclusion Criteria:

  • Upper GI endoscopy performed within a year prior to Visit 1
  • Previous anti-reflux surgery, surgery for peptic ulcer or any form of upper gastrointestinal resective surgery
  • Contra-indication to the Bravo™ procedure such as subjects with a history of bleeding diathesis, strictures anywhere along the GI-tract, esophageal varices, obstructions, or subjects equipped with a pacemaker, an implantable cardiac defibrillator or an implantable neurostimulator (NB: subjects with severe esophagitis (grade D) confirmed by endoscopy at Visit 2 can continue the study without performing the Bravo™ procedure)
Sexes Eligible for Study: All
18 Years to 79 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Canada,   Denmark,   Germany,   Norway,   Sweden,   United Kingdom
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Study Director: AstraZeneca Nexium Medical Science Director, MD AstraZeneca
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP